UBS Group
MPLT

UBS Group’s MapLight Therapeutics MPLT Stock Holding History

UBS Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37M Sell
122,028
-114,484
-48% -$3.29M ﹤0.01% 4316
2026
Q1 		$4.81M Buy
236,512
+218,222
+1,193% +$3.9M ﹤0.01% 4115
2025
Q4 		$321K Buy
+18,290
New +$306K ﹤0.01% 6322

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's MPLT Position: Q2 2026 in Review

UBS Group reduced its MapLight Therapeutics (MPLT) stake by 48% in Q2 2026, selling an estimated $3.29M and leaving 122,028 shares worth $4.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4316.

UBS Group first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.81M in Q1 2026. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • UBS Group held 122,028 shares of MapLight Therapeutics worth $4.37M as of Q2 2026.
  • UBS Group sold 114,484 MapLight Therapeutics shares in Q2 2026, an estimated $3.29M.
  • MapLight Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4316 holding.
  • UBS Group first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • UBS Group's MapLight Therapeutics position peaked at $4.81M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.